Holy Stone Healthcare Co., Ltd
Clinical trials sponsored by Holy Stone Healthcare Co., Ltd, explained in plain language.
-
One patient keeps receiving experimental colorectal cancer drug pair
Disease control Expanded access (ended)This expanded access program provides continued treatment with CA102N plus lonsurf to a single patient with advanced or metastatic colorectal cancer. The patient had already completed at least 12 cycles of the same combination in an earlier clinical study. Expanded access allows …
Sponsor: Holy Stone Healthcare Co., Ltd • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a hyaluronic acid drug combo outperform bevacizumab in Hard-to-Treat colon cancer?
Disease control PausedResearchers are testing whether adding an experimental drug called CA102N to the chemotherapy TAS-102 helps control metastatic colorectal cancer better than adding bevacizumab to TAS-102. The trial enrolls about 100 adults whose cancer has grown after standard chemotherapy. Parti…
Phase 2 • Sponsor: Holy Stone Healthcare Co., Ltd • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC